Render Target: STATIC
Render Timestamp: 2024-10-24T10:18:52.915Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-04-05 20:44:34.120
Product last modified at: 2024-10-04T13:00:09.857Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

DHFR Antibody #45710

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 22
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    DHFR Antibody recognizes endogenous levels of total DHFR protein. This antibody does not cross-react with DHFRL1 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human DHFR protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Dihydrofolate reductase (DHFR) catalyzes tetrahydrofolate regeneration through the reduction of dihydrofolate using NADPH as a cofactor (1). As a key enzyme in folate metabolism, DHFR is ubiquitously expressed in the mitochondria, and is essential for the synthesis of purines, pyrimidines, and some amino acids (2). DHFR is capable of translational autoregulation by binding within the coding region of its own mRNA sequence to repress cellular DHFR protein levels (3). Mutations in the DHFR gene are known to cause inborn errors of folate metabolism resulting in megaloblastic anemia, pancytopenia, and severe cerebral folate deficiency (4). Because tetrahydrofolate is essential for DNA synthesis, cell growth, and proliferation, DHFR is a target of chemotherapeutic agents (e.g., methotrexate and pemetrexed) used in the treatment of many cancer types (5). Increased expression of DHFR has also been identified as a potential mechanism for tumor resistance to methotrexate, and therefore has been utilized as a clinical biomarker to predict patient responsiveness to folate antagonists (6,7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.